Strategies to Increase the Value of Drug Therapy

Strategies to Increase the Value of Drug Therapy

Value is a concept that concerns all healthcare stakeholders.

Five things for pharma marketers to know: Monday, April 27

Five things for pharma marketers to know: Monday, April 27

More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market

Tecfidera sales slow, Biogen to maintain "significant" sales force

Tecfidera sales slow, Biogen to maintain "significant" sales force

The drugmaker said its top-selling multiple-sclerosis drug Tecfidera's slowdown in sales is due to competition from Plegridy as well as new patient concerns about risks of a rare brain infection.

Five things for pharma marketers to know: Friday, April 24

Five things for pharma marketers to know: Friday, April 24

An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo

Merck HCV med's efficacy matches competitors'

Merck HCV med's efficacy matches competitors'

The drugmaker touted new data for its doublet regimen at the International Liver Congress, but it will likely have to look to the margins to find an underserved patient population.

Lilly sees sales fall but reaffirms 2015 revenue guidance

Lilly sees sales fall but reaffirms 2015 revenue guidance

First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.

Mylan's generic Sovaldi launches in India

The hepatitis-C drug is being sold under the name MyHep.

Five things for pharma marketers to know: Thursday, April 23

Five things for pharma marketers to know: Thursday, April 23

Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales

Sales rise as Amgen outlines cardiovascular strategy

Sales rise as Amgen outlines cardiovascular strategy

Established products fueled at 12% jump in first-quarter sales.

Actavis case may not serve as Namenda precedent

A court sided with Actavis in one product-hopping lawsuit for acne drug Doryx.

FDA grants Pfizer lung-cancer drug Breakthrough Designation

Xalkori received the designation to treat a new subset of non-small cell lung cancer patients.

Five things for pharma marketers to know: Wednesday, April 22

Five things for pharma marketers to know: Wednesday, April 22

Study finds vaccines still not linked to autism; investments in healthcare start-ups hit record high this year; biosimilars are already bearing down on prices overseas

Almost one-third of physicians participated in an ACO last year: Medscape

Despite increasing income, many doctors are turning away from self-employment.

Five things for pharma marketers to know: Tuesday, April 21

Five things for pharma marketers to know: Tuesday, April 21

Teva proposes acquisition of Mylan; start-up offers BRCA testing for $249; Botox receives another label expansion

Merck files Keytruda for lung cancer, eyes first-line niche

Merck files Keytruda for lung cancer, eyes first-line niche

Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.

FDA takes unusual stance on ALS drug

FDA takes unusual stance on ALS drug

The FDA asked private biotech Genervon to release all available clinical trial data for its experimental ALS treatment.

Conflict-of-interest rules spur $23M investment

Conflict-of-interest rules spur $23M investment

Schools spent $23 million to bring conflict-of-interest policies in line with regulations aimed at ensuring federally funded research is unbiased.

J&J to pay $63M in Motrin case

A Massachusetts court upheld a 2013 decision that the drugmaker failed to provide sufficient risk information for Children's Motrin.

Five things for pharma marketers to know: Monday, April 20

Five things for pharma marketers to know: Monday, April 20

Teva eyes Mylan takeover; Keytruda shown to improve survival, shrink tumors in melanoma; ADHD abuse may follow grads into workforce.

graphic TEST

Five things for pharma marketers to know: Friday, April 17

Five things for pharma marketers to know: Friday, April 17

The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down

Five things for pharma marketers to know: Thursday, April 16

Five things for pharma marketers to know: Thursday, April 16

FDA approves Amgen heart failure drug; Pfizer halts breast-cancer drug trial over positive results; 30% of study participants asked docs about drug after seeing or reading an ad

FDA committee recommends label change for Onglyza

FDA committee recommends label change for Onglyza

Despite an FDA committee voting that AstraZeneca's diabetes medication carries an acceptable heart risk, analysts say a Merck study will determine the DPP-IV category's fate.

Biogen, PatientsLikeMe use Fitbit to better understand MS

Biogen, PatientsLikeMe use Fitbit to better understand MS

The drugmaker and patient network teamed up to establish a formal framework for deploying activity trackers for patients with MS and for capturing that data.

Novartis leukemia drug ups progression-free survival

Late-stage results show Arzerra patients have a median progression-free survival rate almost double that of chemotherapy-only patients.

Five things for pharma marketers to know: Wednesday, April 15

Five things for pharma marketers to know: Wednesday, April 15

An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money

J&J reports quarterly boost in drug sales

J&J reports quarterly boost in drug sales

The company reported $7.7 billion in pharma revenue in the first quarter despite a drop in overall sales and profit.

Five things for pharma marketers to know: Tuesday, April 14

Five things for pharma marketers to know: Tuesday, April 14

IBM takes on healthcare data; Mylan settled a lawsuit allowing it to launch generic Viagra by 2017; an FDA committee will meet today to discuss Onglyza

US drug spending shows reliance on specialty Rx

US drug spending shows reliance on specialty Rx

Americans spent 13.1% more on prescription medications in 2014 than they did in 2013, but recent launches indicate competition in the specialty drug space is going to heat up.

ResearchKit: A Medical Research Revolution?

ResearchKit: A Medical Research Revolution?

Apple is putting the power of clinical trials in our pockets with ResearchKit.

Practice Fusion partners with AstraZeneca

Physicians will be notified when patient care is not meeting national guidelines for COPD and asthma.

GSK considering change to sales compensation model

The British drugmaker is reviewing the patient-oriented sales model it introduced in 2011.

Five things for pharma marketers to know: Monday, April 13

Five things for pharma marketers to know: Monday, April 13

Sanofi won't discount new insulin; Takeda appoints new US business head; insurers push back on expensive preventative genetic tests

Five things for pharma marketers to know: Friday, April 10

Five things for pharma marketers to know: Friday, April 10

AstraZeneca diabetes drug may have increased mortality rate; Pfizer accused of knowing about birth defect risks from Zoloft; Eisai to cut 25% of its US workforce

Patients do not feel connected to pharma

Patients do not feel connected to pharma

Wego Health says fixing this problem requires incorporating patient perspectives before and after a product launch.

Pfizer offers grants for PCSK9 research

The drugmaker is calling on researchers to investigate PCSK9s in specific areas of interest.

Doximity to launch Apple Watch app

The app for the smartwatch includes secure encrypted messaging.

Five things for pharma marketers to know: Thursday, April 9

Five things for pharma marketers to know: Thursday, April 9

Novartis reported highest drug sales in 2014; state Medicaid programs spent $1.33 billion on hepatitis-C drugs; former FDA commissioner argues against shortening regulatory review times

FDA Onglyza panel review set for Tuesday

FDA Onglyza panel review set for Tuesday

The panel will focus on heart failure hospitalization rates associated with the diabetes medication.

The Delicate Human Side of Marketing Science

The Delicate Human Side of Marketing Science

For all the scientific tools that have fallen into our hands in the past few years, we are still largely falling short in our efforts to influence our audiences' behaviors.

Mylan plans to acquire OTC and generic drugmaker Perrigo

Generic giant Mylan proposed a deal valued at $30 billion to acquire Perrigo Company.

Pharma tablet presentations falling short

A study said many sales presentations fail to resonate with payer audiences.

Hospira gets fifth FDA warning in two years

The company has received seven warning letters since 2010.

Five things for pharma marketers to know: Wednesday, April 8

Five things for pharma marketers to know: Wednesday, April 8

FDA accepts previously rejected Novo Nordisk insulin application; Merck HCV doublet regimen receives Breakthrough designation for patients with kidney disease; researchers say that rising costs for cancer drugs aren't reasonable

High cancer costs associated with better outcomes

High cancer costs associated with better outcomes

Researchers say countries that spend the most on cancer care have better outcomes, but the explanation behind improved mortality is not clear.

How to Make DTC Ad 'Warnings' More Effective

How to Make DTC Ad 'Warnings' More Effective

A more general warning encourages consumers to engage in a personal discussion with their doctor about a drug, and it promotes engagement with longer-format printed or digitally-delivered information.

Five things for pharma marketers to know: Tuesday, April 7

Five things for pharma marketers to know: Tuesday, April 7

Merck funds protein-degrading technology; Shire expects approval for a new ADHD medication in 2017; state biosimilar notification laws focus on subtext

Drugmakers weigh more use of digital

Drugmakers weigh more use of digital

The pharma sales model increasingly relies on key account managers rather than sales reps.

Rituxan may have rare-disease use

The cancer and immunology drug may help patients with a condition that affects two people in every one million.

FDA will study the impact prices have on Rx purchases

The study will include DTC and DTP advertising.

Five things for pharma marketers to know: Monday, April 6

Five things for pharma marketers to know: Monday, April 6

Pfizer exec said biosimilar interchangeability definition not happening anytime soon; AARP launches digital health tech studies with Pfizer and UnitedHealthcare; BMS inks gene therapy collaboration deal

Five things for pharma marketers to know: Friday, April 3

Five things for pharma marketers to know: Friday, April 3

Hedge fund activist challenges Shire patents; CMS issues documents on biosimilars; Astellas Pharma and the University of Texas MD Anderson Cancer Center partner on leukemia treatment

Walgreen Co. sues Endo over pay-for-delay

Walgreen alleges Endo conspired to keep generic Opana ER off the market.

Five things for pharma marketers to know: Thursday, April 2

Five things for pharma marketers to know: Thursday, April 2

Celltrion expects its Remicade biosimilar to hit the US this year; Vivus cuts its sales force; BMJ accuses Novartis of interfering with clinical trials

Teva concealed kickbacks in speaker program, former reps allege

Teva concealed kickbacks in speaker program, former reps allege

Two former Teva sales representatives claim the drugmaker used speaker programs to hide kickbacks for prescribing drugs Copaxone and Azilect.

Johnson & Johnson, GSK settle dispute over OTC advertising claims

Johnson & Johnson, GSK settle dispute over OTC advertising claims

Johnson & Johnson alleged that misleading advertising threatened the $13.2 million in average weekly sales it makes during prime allergy sales season.

Japan seeks more OTC medications

The government is asking consumers which ones they prefer.

FDA finalizes opioid guidance

Opioids lacking abuse-foiling technology will remain available.

Five things for pharma marketers to know: Wednesday, April 1

Five things for pharma marketers to know: Wednesday, April 1

Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused

Merck will evaluate Keytruda cancer combo therapy

Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.

Bayer expands MIT/Harvard collaboration

The focus will now include cardiovascular disease.

Five things for pharma marketers to know: Tuesday, March 31

Five things for pharma marketers to know: Tuesday, March 31

Pfizer spent over $1 billion on ads last year; Monday's M&A activity accounted for about 25% of this year's total; Actavis is selling its Australian generics business

Teva will acquire Auspex to fill Copaxone patent hole

Teva will acquire Auspex to fill Copaxone patent hole

The drugmaker known for its massive presence in generics purchased Auspex Pharmaceuticals to bolster its growing specialty business.

Horizon makes $1.1-billion rare-disease push

Horizon makes $1.1-billion rare-disease push

Horizon Pharma's purchase of Hyperion Therapeutics will add two rare-disease drugs to its portfolio.

White House "superbug" plan has five-year goal

The White House's National Action Plan for Reducing Antibiotic-Resistant Bacteria proposal includes $1.2 billion in funding to reduce superbug infections and develop new diagnostics.

Medicare shelled out more than $4.7 billion on hep C last year

Key contributors to the total: Sovaldi, Harvoni and Olysio

Five things for pharma marketers to know: Monday, March 30

Five things for pharma marketers to know: Monday, March 30

UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals

Five things for pharma marketers to know: Friday, March 27

Five things for pharma marketers to know: Friday, March 27

Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system

Diabetes diagnoses jumped as a result of healthcare reform

Diabetes diagnoses jumped as a result of healthcare reform

Diagnoses spiked in states with expanded Medicaid programs. This may mean higher prescription rates, but research shows a lack of diagnoses also has a price.

Shire and Cincinnati Children's Hospital team up in rare diseases

Shire and Cincinnati Children's Hospital team up in rare diseases

The duo hope to begin testing a new treatment within three years.

Researchers say testosterone ads amount to disease mongering

An editorial says the industry's use of terms like "low T" and "andropause" are false and misleading.

Five things for pharma marketers to know: Thursday, March 26

Five things for pharma marketers to know: Thursday, March 26

Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk

Physicians call for emphasis on women's health research and care

Physicians call for emphasis on women's health research and care

Panelists at a healthcare innovation conference said clinical research and local physician practices need to do more for women's health.

Implement a Direct-to-Patient Approach to Increase Patient Engagement and Retention

Implement a Direct-to-Patient Approach to Increase Patient Engagement and Retention

Direct-to-patient approaches can positively impact real world and late phase research programs to increase engagement, retention and data collection.

Bristol-Myers Squibb licenses autoimmune program from Novo Nordisk

The drugmaker inks deal with Novo Nordisk to access its biologic discovery research platform.

Five things for pharma marketers to know: Wednesday, March 25

Five things for pharma marketers to know: Wednesday, March 25

Keytruda trial stopped due to positive results; new bill proposes continuing FDA rare pediatric voucher program; AstraZeneca signs five-year research pact with Harvard Stem Cell Institute

The New Holistic Approach to Leveraging a Multi-Channel Contact Center

The New Holistic Approach to Leveraging a Multi-Channel Contact Center

Delivering smarter dynamic communications rather than static timed communications based on self-reported data can help connect patients to information and support that drive brand loyalty and program success.

Doctors want specifics on biosimilar labels

An Alliance for Safe Biologic Medicines survey shows what doctors mean by biosimilar transparency.

Five things for pharma marketers to know: Tuesday, March 24

Five things for pharma marketers to know: Tuesday, March 24

Angelina Jolie Pitt discloses she had her fallopian tubes and ovaries removed; the FDA's Zyprexa investigation was inconclusive; Takeda and ImmunoGen sign a $20-million deal

Pharma DTC spending jumps almost 21% in 2014

Pharma DTC spending jumps almost 21% in 2014

Nielsen data shows pharma spent $4.5 billion on DTC ads last year.

Opioid deterrence may work, labeling rules are coming

Opioid deterrence may work, labeling rules are coming

A painkiller manufacturer said abuse-resistant formula lessens abuse, just as the FDA comes under pressure to finalize labeling guidance.

Harrison and Star names co-president

Mario Muredda and Mardene Miller will serve as co-presidents at the healthcare marketing agency.

Baby boomers are no healthier than others

A study shows that greater access to healthcare and lower smoking rates have not made baby boomers healthier than their parents.

Five things for pharma marketers to know: Monday, March 23

Five things for pharma marketers to know: Monday, March 23

Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases

Five things for pharma marketers to know: Friday, March 20

Five things for pharma marketers to know: Friday, March 20

A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik

ASCO wants to talk value when talking cancer

ASCO wants to talk value when talking cancer

An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.

The Patient Abroad: An Exploration of the Motivations and Impact of Medical Tourism

The Patient Abroad: An Exploration of the Motivations and Impact of Medical Tourism

As global healthcare borders become increasingly blurred, the internationally mobile patient may become a standard patient segment considered in healthcare market research.

Sanofi R&D lead takes aim at global drug regulations

The Paris-based drugmaker's global president of R&D said that jumping through different and inconsistent regulatory hoops puts an "enormous" cost on drugmakers.

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

US pharma market value projected to be $550 billion in five years

US pharma market value projected to be $550 billion in five years

Oncology and diabetes medications are expected to be major areas of growth.

What's Your Connected Health Strategy?

What's Your Connected Health Strategy?

At SXSW, for the first time, health wasn't a breakout topic, but rather a "break-in" topic that had the attention of just about every presenter and attendee.

Medtronic teams up with Glooko

The diabetes device manufacturer will soon work with Glooko's platform.

Pfizer takes issue with Little Remedies

The drugmaker, which markets the Dimetapp cough and cold line, sent a complaint to the Better Business Bureaus.

Five things for pharma marketers to know: Wednesday, March 18

Five things for pharma marketers to know: Wednesday, March 18

GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data

23andMe will harness genetic research in new drug discovery unit

23andMe will harness genetic research in new drug discovery unit

The personal genetics company created a therapeutics group to extricate new drug targets from its research database.

Customizing HCP Data In a Challenging Healthcare Environment

Customizing HCP Data In a Challenging Healthcare Environment

Traditional tactics of connecting with physicians are quickly becoming obsolete.

Obesity medications still a hard sell

Increased FDA scrutiny has not garnered trust for the new medications.

Five things for pharma marketers to know: Tuesday, March 17

Five things for pharma marketers to know: Tuesday, March 17

Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing

PCSK9 drugs show viability, tolerability

PCSK9 drugs show viability, tolerability

Amgen and Sanofi/Regeneron shared clinical trial data that shows PCSK9 inhibitors dropped LDL levels by around 60%.

FDA approves Boston Scientific atrial fibrillation device

The approval follows three advisory panel reviews and a complete response letter.

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters